GOCUR

Gocur is a pre-clinical stage biotechnology company focused on developing a new class of small molecule therapeutics that target GTPases, a family of proteins often considered undruggable. By leveraging a proprietary platform that identifies unique binding pockets on these proteins, the company aims to address high-value targets in oncology and other therapeutic areas. Gocur's approach focuses on modulating the activity of key signaling nodes to overcome resistance and improve outcomes for patients with difficult-to-treat cancers. The company is currently advancing its lead programs through early-stage discovery and validation.